| Literature DB >> 24485048 |
Sílvia Cg Moura-Tonello1, Anielle Cm Takahashi1, Cristina O Francisco1, Sérgio Lb Lopes2, Adriano M Del Vale1, Audrey Borghi-Silva1, Angela Mo Leal2, Nicola Montano3, Alberto Porta4, Aparecida M Catai1.
Abstract
BACKGROUND: Individuals with diabetes may develop cardiac autonomic dysfunction that may be evaluated by heart rate variability (HRV). The aim was evaluated heart rate variability (HRV) of individuals with type 2 diabetes, without cardiovascular autonomic neuropathy (CAN), in response to active postural maneuver by means of nonlinear analysis (symbolic analysis, Shannon and conditional entropy) and correlate HRV parameters between them, glycated hemoglobin and diabetes duration.Entities:
Year: 2014 PMID: 24485048 PMCID: PMC3930297 DOI: 10.1186/1758-5996-6-13
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Characteristics of evaluated groups
| Age (years) | 50.53 ± 6.96 | 50.26 ± 7.96 | 0.345 |
| Body mass (Kg) | 86.64 ± 13.86 | 80.24 ± 9.38 | 0.057 |
| Height (m) | 1.74 ± 0.09 | 1.75 ± 0.08 | 0.823 |
| BMI (Kg/m2) | 28.26 ± 4.13 | 26.21 ± 1.77 | 0.062 |
| Percentage of total body fat | 24.94 ± 6.20 | 23.38 ± 3.61 | 0.384 |
| VO2 peak (ml/min) | 1672.05 ± 345.01 | 1850.89 ± 238.09 | 0.070 |
| Time of diabetes (years) | 11.13 ± 6.41 | - | - |
| | | | |
| PCR (mg/dL) | 1.12 ± 1.48 | 0.69 ± 0.66 | 0.874 |
| HbA1c (%) | 8.54 ± 2.15 | 5.85 ± 0.30 | <0.001* |
| HbA1c (mmol/mol) | 69.80 ± 23.55 | 40.44 ± 3.26 | <0.001* |
| Estimated mean glycemia (mg/dL) | 197.79 ± 61.91 | 119.47 ± 9.95 | <0.001* |
| Total cholesterol (mg/dL) | 193.79 ± 28.61 | 198.21 ± 39.33 | 0.635 |
| HDL-cholesterol (mg/dL) | 45.37 ± 10.32 | 46.79 ± 11.02 | 0.573 |
| LDL-cholesterol (mg/dL) | 113.53 ± 32.12 | 119.26 ± 30.62 | 0.253 |
| VLDL-cholesterol (mg/dL) | 33.84 ± 18.49 | 31.05 ± 16.11 | 0.452 |
| Triglycerides (mg/dL) | 170.47 ± 92.57 | 156.37 ± 80.06 | 0.093 |
| | | | |
| Hypertension | 2 (10.53%) | - | - |
| Obesity | 5 (26.31%) | - | - |
| Dyslipidemia | 7 (36.84%) | 9 (47.37%) | - |
| | | | |
| Oral hypoglycemic drugs | 8 (42.11%) | - | - |
| Insulin | 4 (21.05%) | - | - |
| Oral hypoglycemic drugs + insulin | 4 (21.05%) | | |
| Anti-hypertensive drugs | 5 (26.31%) | - | - |
| ACE Inhibitor | 1 (5.26%) | - | - |
| - Calcium channel blocker (amlodipina) | 1 (5.26%) | - | - |
| - Angiotensin II receptor antagonist | 2 (10.53%) | - | - |
| - Hydrochlorothiazide | 1 (5.26%) | - | - |
| - Clonidine | 1 (5.26%) | - | - |
| - Hypolipidemic drug | 2 (10.53%) | 3 (15.79%) | |
| | | | |
| E/I | 1.27 ± 0.20 | 1.29 ± 0.16 | 0.352 |
| ΔIE | 18.53 ± 14.94 | 16.73 ± 8.82 | 0.494 |
The data are presented in mean ± standard deviation. T2D = group with type 2 diabetes; CG = Control Group; BMI = body mass index; VO2 peak = oxygen consumption at peak of physical effort; PCR = C-reactive protein; HbA1c = glycated hemoglobin.*p < 0.05.
Systolic and diastolic blood pressure (mmHg), heart rate (bpm), R-R interval (RRi) and heart rate variance (VAR)
| SBP (mmHg) | 135 ± 16.4 | (126.2–143.8) | 128.8 ± 16.0 | (120.2–137.3) | 129.0 ± 9 | (124.3–133.9) | 122.2 ± 11.00 | (116.4–128.0) | 0.068 | 0.056 | 0.926 |
| DBP (mmHg) | 86.3 ± 12.0 | (79.8–92.7) | 82.8 ± 11.0 | (77–88.7) | 82.2 ± 8 | (78–86.4) | 76.4 ± 20.3 | (65.6–87.3) | 0.131 | 0.182 | 0.735 |
| HR (bpm) | 72.8 ± 8.7 | (68.6–77.0) | 83.3 ±11.5 | (77.7–88.8) | 67.3 ± 10.4 | (62.3–72.3) | 81.1 ± 13.5 | (74.6–87.6) | 0.140 | <0.001* | 0.517 |
| RRi mean (ms) | 836.4 ± 106.1 | (785.3–887.6) | 734.4 ± 107.5 | (682.5–786.2) | 911.3 ± 135.3 | (846.1–976.6) | 760.1 ± 131.7 | (696.7–823.6) | 0.074 | <0.001* | 0.378 |
| VAR (ms2) | 485.4 ± 304.3 | (338.8–632.1) | 327.0 ± 197.1 | (232.0–422.0) | 1010.6 ± 745 | (651.6–1369.7) | 763.9 ± 623.6 | (463.3–1064.4) | <0.001* | 0.187 | 0.885 |
The data are presented in mean ± standard deviation (Mean ± SD) and confidence intervals of mean (CI). T2D = group type 2 diabetes; CG = Control Group; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; iRR = R-R interval between R waves; VAR = variance of RRi; *p < 0.05.
Figure 1Symbolic dynamics of HRV for individuals with type 2 diabetes (T2D) and and control group (CG). The symbol *indicates p <0.05 and † indicates p <0.001. A: 0V% index; B: 1V% index; C: 2LV% index; D: 2UV% index; E: SE = Shannon entropy; F: NCI = normalized complexity index.
Correlation between the parameters of heart rate variability and glycated hemoglobin, duration of diabetes and indexes of slow deep breathing in T2D
| Supine | | | | | | |
| HbA1c (%) | r = −0.03 | r = −0.07 | r = −0.10 | r = 0.20 | r = 0.01 | r = − 0.03 |
| | ||||||
| Duration of Diabetes | r = 0.02 | r = 0.17 | r = 0.30 | r = −0.25 | r = 0.12 | r = −0.19 |
| | ||||||
| E/I | r = −0.24 | r = 0.35 | r = 0.13 | r = 0.18 | r = 0.16 | r = 0.31 |
| | ||||||
| ΔIE | r = 0.08 | r = 0.256 | r = − 0.19 | r = − 0.03 | r = − 0.24 | r = 0.21 |
| | ||||||
| Orthostatic | | | | | | |
| HbA1c (%) | ||||||
| | ||||||
| Duration of Diabetes | ||||||
| | ||||||
| E/I | r = −0.16 | r = 0.22 | r = − 0.10 | r = 0.13 | r = 0.01 | r = 0.14 |
| | ||||||
| ΔIE | r = 0.23 | r = − 0.274 | r = − 0.33 | r = 0.14 | r = − 0.34 | r = 0.18 |
T2D = group type 2 diabetes; Symbolic analysis indexes (0V%, 1V%, 2LV% and 2UV%); SE = Shannon Entropy; CI = complexity Index; NCI = normalized complexity index; E/I = relationship between expiration and inspiration; ΔIE = heart rate during inspiration - heart rate during expiration. There were no significant correlations.
Figure 2Flow diagram indicating sampling loss in the study.